The Research Progress on Radiation Resistance of Cervical Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Apr 23

PMID 38651153

Authors

Meili Liang

Liying Sheng

Yumin Ke

Zhuna Wu

Affiliations

Soon will be listed here.

Abstract

Cervical carcinoma is the most prevalent gynecology malignant tumor and ranks as the fourth most common cancer worldwide, thus posing a significant threat to the lives and health of women. Advanced and early-stage cervical carcinoma patients with high-risk factors require adjuvant treatment following surgery, with radiotherapy being the primary approach. However, the tolerance of cervical cancer to radiotherapy has become a major obstacle in its treatment. Recent studies have demonstrated that radiation resistance in cervical cancer is closely associated with DNA damage repair pathways, the tumor microenvironment, tumor stem cells, hypoxia, cell cycle arrest, and epigenetic mechanisms, among other factors. The development of tumor radiation resistance involves complex interactions between multiple genes, pathways, and mechanisms, wherein each factor interacts through one or more signaling pathways. This paper provides an overview of research progress on an understanding of the mechanism underlying radiation resistance in cervical cancer.

Citing Articles

TIAM2S Operates Multifaced Talents to Alleviate Radiosensitivity, Restrict Apoptosis, Provoke Cell Propagation, and Escalate Cell Migration for Aggravating Radioresistance-Intensified Cervical Cancer Progression.

Chuang P, Su W, Hsieh C, Huang E Cells. 2025; 14(5).

PMID: 40072068 PMC: 11898548. DOI: 10.3390/cells14050339.

Delta-radiomics analysis based on magnetic resonance imaging to identify radiation proctitis in patients with cervical cancer after radiotherapy.

Xue J, Wu M, Zhang J, Yang J, Lv G, Qu B Front Oncol. 2025; 15:1523567.

PMID: 39944831 PMC: 11813761. DOI: 10.3389/fonc.2025.1523567.

LncRNA AFAP1-AS1 exhibits oncogenic characteristics and promotes gemcitabine-resistance of cervical cancer cells through miR-7-5p/EGFR axis.

Wang C, Zhang T, Zhang C Oncol Res. 2024; 32(12):1867-1879.

PMID: 39574469 PMC: 11576921. DOI: 10.32604/or.2024.044547.

The value of a multimodal approach combining radical surgery and intraoperative radiotherapy in the recurrence treatment of gynecological malignancies - analysis of a large patient cohort in a tertiary care center.

Sprave T, Stoian R, Volegova-Neher N, Gainey M, Kollefrath M, Baltas D Radiat Oncol. 2024; 19(1):147.

PMID: 39456020 PMC: 11515090. DOI: 10.1186/s13014-024-02537-z.

References

Wu N, Zhang X, Zhu M, Fang C, Liu X, Wang Y . promoter methylation predicts cervical cancer radiosensitivity and ZNF582 protein overexpression reduces radiosensitivity by cell cycle arrest in S phase. Epigenetics. 2022; 17(12):1786-1799. PMC: 9621039. DOI: 10.1080/15592294.2022.2080995. View

Csibi A, Fendt S, Li C, Poulogiannis G, Choo A, Chapski D . The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell. 2021; 184(8):2256. DOI: 10.1016/j.cell.2021.03.059. View

Jiang W, Ouyang X, Ji Z, Shi W, Wu Y, Yao Q . The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer. Cancer Lett. 2023; 556:216064. DOI: 10.1016/j.canlet.2023.216064. View

Luo J, Wang W, Tang Y, Zhou D, Gao Y, Zhang Q . mRNA and methylation profiling of radioresistant esophageal cancer cells: the involvement of Sall2 in acquired aggressive phenotypes. J Cancer. 2017; 8(4):646-656. PMC: 5370508. DOI: 10.7150/jca.15652. View

Chen L, Heikkinen L, Wang C, Yang Y, Sun H, Wong G . Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 2018; 20(5):1836-1852. PMC: 7414524. DOI: 10.1093/bib/bby054. View

Smith H, Southgate H, Tweddle D, Curtin N . DNA damage checkpoint kinases in cancer. Expert Rev Mol Med. 2020; 22:e2. DOI: 10.1017/erm.2020.3. View

Ghose S, Holloway L, Lim K, Chan P, Veera J, Vinod S . A review of segmentation and deformable registration methods applied to adaptive cervical cancer radiation therapy treatment planning. Artif Intell Med. 2015; 64(2):75-87. DOI: 10.1016/j.artmed.2015.04.006. View

Cabrera-Licona A, Perez-Anorve I, Flores-Fortis M, Del Moral-Hernandez O, Gonzalez-de la Rosa C, Suarez-Sanchez R . Deciphering the epigenetic network in cancer radioresistance. Radiother Oncol. 2021; 159:48-59. DOI: 10.1016/j.radonc.2021.03.012. View

Pedroza-Torres A, Campos-Parra A, Millan-Catalan O, Loissell-Baltazar Y, Zamudio-Meza H, Cantu de Leon D . MicroRNA-125 modulates radioresistance through targeting p21 in cervical cancer. Oncol Rep. 2018; 39(3):1532-1540. DOI: 10.3892/or.2018.6219. View

10.

Yu D, Li Y, Ming Z, Wang H, Dong Z, Qiu L . Comprehensive circular RNA expression profile in radiation-treated HeLa cells and analysis of radioresistance-related circRNAs. PeerJ. 2018; 6:e5011. PMC: 6005163. DOI: 10.7717/peerj.5011. View

11.

Williamson C, Liu H, Mayadev J, Mell L . Advances in External Beam Radiation Therapy and Brachytherapy for Cervical Cancer. Clin Oncol (R Coll Radiol). 2021; 33(9):567-578. DOI: 10.1016/j.clon.2021.06.012. View

12.

Wu N, Zhang X, Chu T, Zhu S, Deng Y, Zhou Y . High methylation of in cervical adenocarcinoma affects radiosensitivity and prognosis. Ann Transl Med. 2019; 7(14):328. PMC: 6694254. DOI: 10.21037/atm.2019.06.15. View

13.

Ren C, Cheng X, Lu B, Yang G . Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour.... Eur J Cancer. 2013; 49(18):3889-99. DOI: 10.1016/j.ejca.2013.07.140. View

14.

Chuang P, Chen P, Wang C, Su W, Chen Y, Huang E . Manifests Multifaceted Features to Intensify Radiosensitivity, Escalate Apoptosis, and Revoke Cell Migration for Palliating Radioresistance-Enhanced Cervical Cancer Progression. Int J Mol Sci. 2022; 23(10). PMC: 9141925. DOI: 10.3390/ijms23105524. View

15.

Nishiyama A, Nakanishi M . Navigating the DNA methylation landscape of cancer. Trends Genet. 2021; 37(11):1012-1027. DOI: 10.1016/j.tig.2021.05.002. View

16.

Wu Y, Song Y, Wang R, Wang T . Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer. 2023; 22(1):96. PMC: 10268375. DOI: 10.1186/s12943-023-01801-2. View

17.

Chen L, Shan G . CircRNA in cancer: Fundamental mechanism and clinical potential. Cancer Lett. 2021; 505:49-57. DOI: 10.1016/j.canlet.2021.02.004. View

18.

Zingkou E, Pampalakis G, Sotiropoulou G . Cocktails of KLK5 Protease Inhibitors and Anti-TNFα Therapeutics: an Effective Treatment for Netherton Syndrome. J Clin Immunol. 2022; 42(3):597-605. DOI: 10.1007/s10875-021-01195-0. View

19.

Olivares-Urbano M, Grinan-Lison C, Marchal J, Isabel Nunez M . CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer. Cells. 2020; 9(7). PMC: 7407195. DOI: 10.3390/cells9071651. View

20.

Zhao H, Zheng G, Li G, Xin L, Wang Y, Chen Y . Long noncoding RNA LINC00958 regulates cell sensitivity to radiotherapy through RRM2 by binding to microRNA-5095 in cervical cancer. J Cell Physiol. 2019; 234(12):23349-23359. DOI: 10.1002/jcp.28902. View